| Code | CSB-RA011614MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TAVO-103, targeting interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B plays a critical role in initiating and amplifying inflammatory cascades by promoting fever, activating endothelial cells, and stimulating the production of additional inflammatory mediators. Dysregulated IL1B signaling is implicated in numerous pathological conditions, including autoinflammatory diseases, rheumatoid arthritis, type 2 diabetes, cardiovascular disease, and various cancers where it contributes to tumor progression and metastasis.
TAVO-103 represents a therapeutic antibody designed to neutralize IL1B activity, offering researchers a tool to investigate IL1B-mediated pathways and inflammatory mechanisms. This biosimilar provides a cost-effective alternative for studies examining cytokine biology, inflammatory disease models, and therapeutic intervention strategies. It supports investigations into IL1B's role in disease pathogenesis, immune cell activation, and potential therapeutic targeting in conditions characterized by chronic or excessive inflammation.
There are currently no reviews for this product.